MDSpire - Takeaway
Feature

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

Share

  • 1

    Dr. Vivek Subbiah appointed at Stanford Cancer Institute.

  • 2

    Plans to lead phase 1 trials.

  • 3

    Focus on tumor-agnostic precision therapies.

  • 4

    Over 150 trials as principal investigator.

  • 5

    Previous role at Sarah Cannon Research Institute.

  • 6

    Goals include enhancing access to innovative treatments.

  • 7

    Aims to integrate research and patient-centered care.

  • 8

    Recognized as a top influencer in oncology.

Original Source(s)

Stanford Names Leader for Drug Development and Precision Oncology

  • by The ASCO Post Staff

  • March 24, 2026

Related Content

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...